Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20684994 | 0.84 | BRD4 (0.38) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL20690375 | 0.78 | CHRM2 (0.37) | LMNAMEN1KMT2A | |
| SCHEMBL21982244 | 0.76 | BRD4 (0.44) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL20684997 | 0.74 | RXFP1 (0.40) | MAPTLMNASMN1; SMN2POLBMEN1 | |
| SCHEMBL9369457 | 0.68 | CYP3A4 (0.47) | MAPTLMNASMN1; SMN2POLBMEN1 | |
| SCHEMBL15046557 | 0.68 | CHRM2 (0.60) | — | |
| SCHEMBL12963725 | 0.68 | ADRA2A (0.47) | MEN1KMT2A | |
| SCHEMBL8936588 | 0.68 | MAPT (0.50) | MAPTLMNASMN1; SMN2POLBMEN1 | |
| SCHEMBL9099840 | 0.68 | MAPT (0.58) | MAPTLMNASMN1; SMN2POLBMEN1 | |
| SCHEMBL23835579 | 0.67 | CHRM2 (0.50) | MAPTLMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347742-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347742-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | MAPT 4825/4885LMNA 4267/4885SMN1; SMN2 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.